Gilead data best response rates seen in HDV

Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IIb MYR204 open-label study assessing the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in compensated chronic hepatitis delta virus (HDV) infection.

Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bulevirtide 10 mg with PegIFN was superior to investigational bulevirtide 10mg monotherapy in achieving undetectable HDV RNA at week 24 after the end of treatment (EOT).

"Almost half of people treated with bulevirtide 10mg in combination with PegIFN remained undetectable for HDV RNA one year after treatment cessation"The end of study data presented at the European Association for the Study of the Liver (EASL) Congress 2024, demonstrate that treatment with bulevirtide 10mg alongside PegIFN maintained a 46% rate of undetectable HDV RNA at week 48 after EOT, confirming its potential as a finite therapy for adults living with chronic HDV.